



# MEDICAL POLICY

| MEDICAL POLICY DETAILS |  |
|------------------------|--|
| Medical Policy Title   | ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING  |
| Policy Number          | 7.01.70  |
| Category               | Technology Assessment  |
| Effective Date         | 02/16/06   |
| Revised Date           | 11/16/06, 09/20/07, 10/23/08, 09/17/09, 08/19/10, 07/21/11, 06/21/12, 05/23/13, 04/17/14, 03/19/15, 03/17/16, 03/16/17, 03/15/18, 02/21/19, 02/20/20   |
| Product Disclaimer     | <ul style="list-style-type: none"> <li>• If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply.</li> <li>• If a commercial product (including an Essential Plan product) or a Medicaid product covers a specific service, medical policy criteria apply to the benefit.</li> <li>• If a Medicare product covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit.</li> </ul> |

## POLICY STATEMENT

Based upon our criteria and assessment of the peer-reviewed literature, intracranial percutaneous transluminal angioplasty, with or without stenting, has not been medically proven to be effective and, therefore, is considered **investigational** for treatment of intracranial atherosclerotic stenosis.

*Refer to Corporate Medical Policy # 7.01.60 Extracranial Carotid and Vertebral Artery Angioplasty and Stents.*

*Refer to Corporate Medical Policy #7.01.81 Endovascular Repair (coil embolization) of Intracranial Aneurysms.*

*Refer to Corporate Medical Policy #7.01.82 Endovascular Treatment of Acute Ischemic Stroke (e.g. Mechanical Embolectomy).*

*Refer to Corporate Medical Policy #11.01.03 Experimental and Investigational Services.*

*Refer to Corporate Medical Policy #11.01.10 Clinical Trials.*

## POLICY GUIDELINES

The Federal Employee Health Benefit Program (FEHBP/FEP) requires that procedures, devices or laboratory tests approved by the U.S. Food and Drug Administration (FDA) may not be considered investigational and, thus, these procedures, devices or laboratory tests may be assessed only on the basis of their medical necessity.

## DESCRIPTION

Approximately 750,000 strokes occur in the United States annually, of which 85% are ischemic. A significant number of ischemic strokes are due to intracranial atherosclerosis. Intracranial stenosis may contribute to stroke either by thrombosis or low flow ischemia (symptomatic stenosis) in the absence of collateral circulation. Medical treatment with either antithrombotic therapy or agents to increase mean arterial blood pressure is considered less than optimal, and surgical options have resulted in only minimal success.

Percutaneous transluminal angioplasty (PTA) has been approached cautiously in the intracranial circulation, due to technical difficulties in catheter and stent design, and the risk of embolism. However, improvement in catheter trackability and the increased use of stents have created ongoing interest in exploring PTA as a minimally invasive treatment for the prevention of stroke in patients with intracranial artery stenosis. Most published studies of intracranial PTA have focused on the vertebrobasilar circulation as treatment for symptomatic stenosis. A few studies have explored the use of stents as a

## **Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING**

**Policy Number: 7.01.70**

**Page: 2 of 11**

rescue measure in situations of failed thrombolytic therapy or in patients who are not candidates for thrombolytic treatment.

### **RATIONALE**

Currently, two PTA devices have received approval from the FDA through the humanitarian device exemption (HDE) process. This form of FDA approval is available for devices used to treat conditions with an incidence of 4,000 or less per year, and the FDA only requires data showing “probable safety and effectiveness.”

The Neurolink® System (Guidant Corporation) is indicated for the treatment of patients with recurrent intracranial stroke attributable to atherosclerotic disease refractory to medical therapy in intracranial vessels ranging from 2.5 to 4.5 mm in diameter with greater than or equal to 50% stenosis and that are accessible to the stent system. Patients in this subset have a poor prognosis, and treatment options are limited. A 2004 prospective, nonrandomized, multicenter study (SSYLVIA [Stenting of Symptomatic Atherosclerosis Lesions in the Vertebral or Intracranial Arteries]) investigated the device. The primary endpoint was a composite of stroke and death at 30 days, which occurred in 6.6% of patients. The FDA Summary of Safety and Probable Benefit notes that, in the WASID study of aspirin and warfarin therapy, the rate of fatal or non-fatal stroke was 14.6%, and total/stroke or death was 22.5%. The FDA concluded:

...the probable benefit to health from using the Neurolink System for intracranial stenting for recurrent stroke attributable to intracranial atherosclerosis refractory to medical therapy outweighs the risk of illness or injury, taking into account the probable risks and benefits of currently available devices or alternative forms of treatment, when used as indicated in accordance with the directions of use.

Despite receiving HDE approval from the FDA, the Guidant Corporation no longer manufactures the Neurolink Stent System.

The Wingspan™ Stent System with Gateway™ PTA Balloon Catheter (Boston Scientific) is indicated for improving cerebral artery lumen diameter in patients with intracranial atherosclerotic disease, refractory to medical therapy, in intracranial vessels with greater than or equal to 50% stenosis that are accessible to the system. The Wingspan Stent System consists of a highly flexible, microcatheter-delivered, self-expanding nitinol stent, which may be suitable for lesions in the distal internal carotid and middle cerebral arteries. These lesions are difficult to access with a balloon-mounted stent such as the Neurolink System. The Wingspan was studied in a prospective, multicenter, single-arm trial of 45 patients enrolled at 12 international centers. The primary safety endpoint was similar to that of the SSYLVIA study, i.e., a composite of stroke and death clinical outcomes at 30 days, which occurred in 4.5% of patients. Clinical follow-up (42 patients) and angiographic follow-up (40 patients) were performed at six months. The type and frequency of observed adverse events including stroke were consistent with or lower than similar neurovascular procedures. Therefore, the FDA concluded that the probable benefit to health from using the Wingspan Stent System with Gateway PTA Balloon Catheter for treating transcranial stenosis outweighs the risk of illness or injury when used in accordance with the Instructions for Use and when taking into account the probable risks and benefits of currently available alternative forms of treatment.

The FDA Neurological Devices Panel met on March 23, 2012 to discuss the continued approval of the Wingspan Stent after the poor results of the SAMMPRIS trial. In an informal vote, the panel agreed unanimously that the current data on the device do not support its safety and efficacy as a treatment for ischemic stroke in adults and called for continued research. Based on that meeting, the FDA narrowed the indications for the use of Wingspan (FDA Medwatch Aug 2012), stating:

After reviewing the available safety information, the FDA believes that a very specific group of patients with severe intracranial stenosis and recurrent stroke despite continued medical management – who have not had any new symptoms of stroke within the 7 days prior to planned treatment with Wingspan – may benefit from the use of the device. ...The agency's assessment of benefits and risks for this device considered that these patients are at serious risk of life-threatening stroke and have limited alternative treatment options.

## **Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING**

**Policy Number: 7.01.70**

**Page: 3 of 11**

A 2005 Cochrane review focused on randomized trials of angioplasty of vertebral artery stenosis compared with best medical therapy alone, and included a review of the SSYLVA study and a large number of case series. The authors concluded, "... there is currently insufficient evidence to support the routine use of percutaneous transluminal angioplasty (PTA) and stenting for vertebral artery stenosis. Endovascular treatment of vertebral artery stenosis should only be performed within the context of randomized controlled trials."

In October 2005, the American Society of Interventional and Therapeutic Neuroradiology (ASITN), the Society of Interventional Radiology (SIR), and the American Society of Neuroradiology (ASNR) issued a position statement regarding intracranial angioplasty and stenting for cerebral atherosclerosis. This position statement reviewed a number of case series and also the SSYLVA and Wingspan multi-institutional studies and concluded that sufficient evidence exists to recommend that intracranial angioplasty with or without stenting be offered to symptomatic patients with intracranial stenoses greater than 50% who have failed medical therapy.

A 2006 Cochrane Review focused on angioplasty for intracranial artery stenosis. The authors indicated that no randomized controlled trials were found. There were 79 articles of interest consisting of case series with three or more cases. The safety profile showed an overall perioperative rate of stroke of 7.9% and perioperative stroke or death of 9.5%. The authors concluded that the evidence was insufficient to recommend angioplasty with or without stent placement in routine practice for the prevention of stroke in patients with intracranial artery stenosis. The descriptive studies show that the procedure is feasible, but carries significant morbidity and mortality risks. Evidence from randomized controlled trials is needed to assess the safety of angioplasty and its effectiveness in preventing recurrent stroke.

A 2007 assessment of endovascular stent insertion for intracranial atherosclerotic disease by the National Institute for Health and Clinical Excellence (NICE) concluded:

The evidence on the efficacy of endovascular stent insertion for intracranial atherosclerotic disease is currently inadequate and the procedure poses potentially serious safety concerns. Therefore, this procedure should only be used in the context of clinical research including collecting data which should be submitted to a national register when available. Research should clearly define patient selection and be designed to provide outcome data based on follow-up of at least two (2) years.

Qureshi, *et al.* (2008) reported on a non-randomized comparison (angioplasty was used preferentially in patients with more technically challenging lesions) of 44 patients who underwent angioplasty with or without stenting for symptomatic intracranial stenosis. At 12 months, there were no statistically significant differences between groups. However, there was no comparative medical group, and the sample size was relatively small.

Firoella reported on initial periprocedural experience with the Wingspan Stent in a study of 78 patients, average age 64 years. In this study, 81 of 82 lesions were successfully stented, and percent stenosis was reduced (from 75% to 27% after stent placement). There were five (6.1%) major periprocedural neurologic complications, with four patient deaths within 30 days. Long-term outcomes were not reported in this initial report.

Zaidat, *et al.* (2008) reported on the NIH registry on use of the Wingspan Stent for symptomatic intracranial stenosis. This article reported on 129 patients from 16 medical centers treated with a Wingspan Stent in that registry between November 2005 and October 2006. Patients with symptomatic 70% to 99% intracranial stenosis were enrolled. The technical success rate was 96.7%. The mean pre- and post-stent stenoses were 82% and 20%. The frequency of any stroke, intracerebral hemorrhage, or death within 30 days or ipsilateral stroke beyond 30 days was 14.0% at six months (95% CI = 8.7% to 22.1%). The frequency of 50% or more restenosis on follow-up angiography was 13/52 (25%). The authors concluded that the use of a Wingspan Stent in patients with severe intracranial stenosis is relatively safe, with a moderately high rate of restenosis. They also noted that comparison of the event rates in high-risk patients in warfarin-aspirin symptomatic intracranial disease (WASID) versus that registry did not rule out either that stenting could be associated with a substantial relative risk reduction or has no advantage compared with medical therapy; thus, a randomized trial comparing stenting with medical therapy is needed.

The literature continues to be dominated by single-institution case series, and non-randomized prospective trials. As noted in the 2006 Cochrane Review and NICE assessment, the evidence is insufficient to recommend angioplasty with or

## Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING

Policy Number: 7.01.70

Page: 4 of 11

without stent placement in routine practice for the prevention of stroke in patients with intracranial artery stenosis. Research is needed to clearly define patient selection and must be designed to provide outcome data based on follow-up of at least two years. Given the uncertain impact of this procedure on clinical outcomes, it is considered investigational.

The stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) was a randomized controlled trial (RCT) comparing aggressive medical management alone to aggressive medical management plus stenting in patients with symptomatic cerebrovascular disease and an intracranial stenosis of between 70-99%. That trial used the Wingspan Stent System, implanted by experienced neurointerventionists who had been credentialed to participate in the trial. The authors (Chimowitz, *et al.* 2011) had planned for an enrollment of approximately 750 patients based on power calculations. However, the trial was stopped early for futility after 451 patients had been randomized. The trial was terminated due to an excess of the primary outcome, stroke or death, at 30 days in the stenting group. In the stenting group, the rate of stroke or death at 30 days was 14.7% compared to a rate of 5.8% (p=0.002) in the medical management group. At the time of termination, the mean follow-up was 11.9 months. Kaplan-Meier estimates of the primary outcome of stroke or death at one year was 20.5% in the stenting group, compared to 12.2% (p=0.009) in the medical management group. These results represented an excess rate of early adverse events with stenting over what was expected, together with a decreased rate of stroke and death in the medical management group compared to expected values.

CP Derdeyn and colleagues (2014) reported on the long-term outcome of the SAMMPRIS study. They randomly assigned 451 patients with recent transient ischemic attack or stroke related to 70-99% stenosis of a major intracranial artery to aggressive medical management (antiplatelet therapy, intensive management of vascular risk factors, and a lifestyle-modification program) or aggressive medical management plus stenting with the Wingspan Stent. The primary endpoint was any of the following: stroke or death within 30 days after enrolment, ischemic stroke in the territory of the qualifying artery beyond 30 days of enrolment, or stroke or death within 30 days after a revascularization procedure of the qualifying lesion during follow-up. Primary endpoint analysis of between-group differences with log-rank test was by intention to treat. During a median follow-up of 32.4 months, 34 (15%) of 227 patients in the medical group and 52 (23%) of 224 patients in the stenting group had a primary endpoint event. The cumulative probability of the primary endpoints was smaller in the medical group versus the percutaneous transluminal angioplasty and stenting (PTAS) group (p=0.0252). Beyond 30 days, 21 (10%) of 210 patients in the medical group and 19 (10%) of 191 patients in the stenting group had a primary endpoint. The absolute differences in the primary endpoint rates between the two groups were 7.1% at year one (95% CI 0.2 to 13.8%; p=0.0428), 6.5% at year two (-0.5 to 13.5%; p=0.07) and 9.0% at year three (1.5 to 16.5%; p=0.0193). The occurrence of the following adverse events was higher in the PTAS group than in the medical group: any stroke (59 [26%] of 224 patients vs. 42 [19%] of 227 patients; p=0.0468) and major hemorrhage (29 [13%] of 224 patients vs. 10 [4%] of 227 patients; p=0.0009). CP Derdeyn and colleagues concluded that, for high-risk patients with intracranial stenosis, aggressive medical management is superior to stenting with the Wingspan device at both early and later phases of follow-up.

### CODES

- Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.
- **CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.**
- Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.
- Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN)

#### CPT Codes

| Code        | Description   |
|-------------|---|
| 61630 (E/I) | Balloon angioplasty, intracranial (eg, atherosclerotic stenosis), percutaneous  |
| 61635 (E/I) | Transcatheter placement of intravascular stent(s), intracranial (eg, atherosclerotic stenosis), including balloon angioplasty, if performed |

**Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING**

**Policy Number: 7.01.70**

**Page: 5 of 11**

| <b>Code</b> | <b>Description</b>   |
|-------------|--|
| 36221       | Non-selective catheter placement, thoracic aorta, with angiography of the extracranial carotid, vertebral, and/or intracranial vessels, unilateral or bilateral, and all associated radiological supervision and interpretation, includes angiography of the cervicocerebral arch, when performed  |
| 36223       | Selective catheter placement, common carotid or innominate artery, unilateral, any approach, with angiography of the ipsilateral intracranial carotid circulation and all associated radiological supervision and interpretation, includes angiography of the extracranial carotid and cervicocerebral arch, when performed  |
| 36224       | Selective catheter placement, internal carotid artery, unilateral, with angiography of the ipsilateral intracranial carotid circulation and all associated radiological supervision and interpretation, includes angiography of the extracranial carotid and cervicocerebral arch, when performed  |
| 36228       | Selective catheter placement, each intracranial branch of the internal carotid or vertebral arteries, unilateral, with angiography of the selective vessel circulation and all associated radiological supervision and interpretation (e.g., middle cerebral artery, posterior inferior cerebellar artery) (List separately in addition to code for primary procedure) |

*Copyright © 2020 American Medical Association, Chicago, IL*

**HCPCS Codes**

| <b>Code</b> | <b>Description</b> |
|-------------|--------------------|
| No codes    |                    |

**ICD10 Codes**

| <b>Code</b>                             | <b>Description</b> |
|---|--------------------|
| Investigational for all diagnosis codes |                    |

**REFERENCES**

Abuzinadah AR, et al. Stroke recurrence rates among patients with symptomatic intracranial vertebrobasilar stenosis: systematic review and meta-analysis. J Neurointerv Surg 2016 Feb;8(2):112-6.

\*Adams HP, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007 May;38(5):1655-711.

Aghaebrahim A, et al. Endovascular recanalization of symptomatic intracranial arterial stenosis despite aggressive medical management. World Neurosurg 2019 Mar;123:e693-e699.

\*Al-Ali F, et al. Predictors of unfavorable outcome in intracranial angioplasty and stenting in a single-center comparison: results from the Borgess Medical Center-Intracranial Revascularization Registry. AJNR Am J Neuroradiol 2011 Aug;32(7):1221-6.

\*Al-Ali F, et al. How effective is endovascular intracranial revascularization in stroke prevention? Results from the Borgess Medical Center-Intracranial Revascularization Registry. AJNR Am J Neuroradiol 2011 Aug;32(7):1227-31.

\*Alexander MJ, et al. WEAVE trial: final results in 152 on-label patients. Stroke 2019 Apr;50(4):889-894.

## **Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING**

**Policy Number: 7.01.70**

**Page: 6 of 11**

\*Al Hasan M, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis: more harm than good. Crit Care 2012 May 9;16(3):310.

Al Kasab S, et al. Impact of the new American Heart Association/American Stroke Association definition of stroke on the results of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis trial. J Stroke Cerebrovasc Dis 2017 Jan;26(1):108-115.

Al Said Y, et al. Outcome of intracranial arterial stenting of symptomatic atherosclerotic disease: a single center experience from Saudi Arabia. Neurosciences 2016 Oct;21(4):366-371.

Bai WX, et al. Wingspan stenting can effectively prevent long-term strokes for patients with severe symptomatic atherosclerotic basilar stenosis. Interv Neuroradiol 2016 June;22(3):318-324.

\*Blasel S, et al. Recanalization results after intracranial stenting of atherosclerotic stenoses. Cardiovasc Intervent Radiol 2010 Oct;33(5):914-20.

BlueCross BlueShield Association. Endovascular procedures for Intracranial Arterial Disease (Atherosclerosis and Aneurysms). Medical Policy Reference Manual Policy # 2.01.54. 2019 Apr 08.

\*Bose A, et al. A novel, self-expanding, nitinol stent in medically refractory intracranial atherosclerotic stenoses: the Wingspan study. Stroke 2007 May;38(5):1531-7.

\*Chaudhry SA, et al. The new standard for performance of intracranial angioplasty and stent placement after Stenting versus Aggressive Medical Therapy for Intracranial Arterial Stenosis (SAMMPRIS) Trial. AJNR Am J Neuroradiol 2011 Dec;32(11):E214.

\*Chavent A, et al. Endovascular treatment of symptomatic intracranial atheromatous stenosis: a single center study of 21 consecutive cases. J Neuroradiol 2012 Dec;39(5):332-41.

\*Chimowitz MI, et al. Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011 Sep 15;365(11):993-1003.

Compter A, et al. Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomized open-label phase 2 trial. Lancet Neurol 2015 Jun;14(6):606-14.

\*Costalat V, et al. Endovascular treatment of symptomatic intracranial arterial stenosis: six-year experience in a single-center series of 42 consecutive patients with acute and mid-term results. Neurosurg 2010 Dec;67(6):1505-13.

\*Costalat V, et al. Endovascular treatment of symptomatic intracranial stenosis with Wingspan stent system and gateway PTA balloon: a multicenter series of 60 patients with acute and midterm results. J Neurosurg 2011 Oct;115(4):686-93.

\*Coward LJ, et al. Long-term outcome after angioplasty and stenting for symptomatic vertebral artery stenosis compared with medical treatment in the Carotid And Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. Stroke 2007 May;38(5):1526-30.

\*Coward LJ, et al. Percutaneous transluminal angioplasty and stenting for vertebral artery stenosis. Cochrane Database Syst Rev 2005 Apr 18;(2):CD000516.

\*Cruz-Flores S, Diamond AL. Angioplasty for intracranial artery stenosis. Cochrane Database Syst Rev. 2006 Jul 19;3:CD004133.

\*Derdeyn CP, et al. Impact of operator and site experience on outcomes after angioplasty and stenting in the SAMMPRIS trial. J Neurointerv Surg 2013 Nov;5(6):528-33.

\*Derdeyn CP, et al. Aggressive medical treatment with or without stenting in high-risk patients with intracranial artery stenosis (SAMMPRIS): the final results of a randomized trial. Lancet 2014 Jan 25;383(9914):333-41.

## **Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING**

**Policy Number: 7.01.70**

**Page: 7 of 11**

Derdeyn CP, et al. Nonprocedural symptomatic infarction and in-stent restenosis after intracranial angioplasty in the SAMMPRIS Trial (Stenting and Aggressive medical Management for the prevention of Recurrent Stroke in Intracranial Stenosis). Stroke 2017 June;48(6):1501-1506.

\*Dorn F, et al. Stent angioplasty of intracranial stenosis: single center experience of 54 cases. Clin Neuroradiol 2012 Jun;22(2):149-56.

\*Du B, et al. Long-term outcome of tandem stenting of stenoses of the intracranial vertebrobasilar artery and vertebral ostium. AJNR 2009 Apr;30(4):840-4.

Duan G, et al. Solitaire stents for the treatment of complex symptomatic intracranial stenosis after antithrombotic failure: safety and efficacy evaluation. J Neurointerv Surg 2016 Jul;8(7):680-4.

\*Dumont TM, et al. Revisiting angioplasty without stenting for symptomatic intracranial atherosclerotic stenosis after the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) study. Neurosurgery 2012 Dec;7(6):1103-10.

Dumont TM, et al. Submaximal angioplasty for symptomatic intracranial atherosclerosis: a prospective Phase I study. J Neurosurg 2016 Oct;125(4):964-971.

Feng Z, et al. Enterprise stent for the treatment of symptomatic intracranial atherosclerotic stenosis: an initial experience of 44 patients. BMC Neurol 2015 Oct 8;15:187.

\*Fiorella D, et al. US multicenter experience with the wingspan stent system for the treatment of intracranial atheromatous disease: periprocedural results. Stroke 2007 Mar;38(3):881-7.

\*Fiorella D, et al. Detailed analysis of periprocedural strokes in patients undergoing intracranial stenting in Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS). Stroke 2012 Oct;43(10):2682-8.

\*Gao X, et al. Wingspan stent-assisted coiling of intracranial aneurysms with symptomatic parent artery stenosis: experience in 35 patients with mid-term follow-up results. Eur J Radiol 2012 May;81(5):e750-6.

Geng X, et al. Comparison of self-expanding stents with distal embolic protection to balloon-expandable stents without a protection device in the treatment of symptomatic vertebral artery origin stenosis: a prospective randomized trial. J Endovasc Ther 2015 Jun;22(3):436-44.

\*Groschel K, et al. A systematic review on outcome after stenting for intracranial atherosclerosis. Stroke 2009 May;40(5):e340-7.

\*Gupta R, et al. Safety, feasibility, and short-term follow-up of drug-eluting stent placement in the intracranial and extracranial circulation. Stroke 2006 Oct;37(10):2562-6.

\*Hartmann M, et al. Angioplasty and stenting of intracranial stenosis. Curr Opin Neurol 2005 Feb;18(1):39-45.

\*Henkes H, et al. Treatment of intracranial atherosclerotic stenoses with balloon dilatation and self-expanding stent deployment (WingSpan). Neuroradiol 2005 Mar;47(3):222-8.

\*Higashida RT, et al. Intracranial angioplasty & stenting for cerebral atherosclerosis: a position statement of the American Society of Interventional and Therapeutic Neuroradiology, Society of Interventional Radiology, and the American Society of Neuroradiology. J Vasc Interv Radiol 2005 Oct;16(10):1281-5.

Hussain M, et al. Spanning from the West to East: an updated review on endovascular treatment of intracranial atherosclerotic disease. Aging Dis 2017 April 1;8(2):196-202.

\*Jiang WJ, et al. Apollo stent for symptomatic atherosclerotic intracranial stenosis: study results. AJNR 2007 May;28(5):830-4.

## **Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING**

**Policy Number: 7.01.70**

**Page: 8 of 11**

\*Jiang WJ, et al. Outcomes of patients with > 70% symptomatic intracranial stenosis after wingspan stenting. Stroke 2011 Jul;42(7):1971-5.

Kadooka K, et al. Safety and efficacy of balloon angioplasty in symptomatic intracranial stenosis: A systematic review and meta-analysis. J Neuroradiol 2019 Mar 9. [Epub ahead of print]

Karanam LSP, et al. Balloon angioplasty for intracranial atherosclerotic disease: a multicenter study. J vasc Interv Neurol 2017 June;9(4):29-34.

Ko JK, et al. Percutaneous transluminal angioplasty and stenting for severe stenosis of the intracranial extradural internal carotid artery causing transient ischemic attack or minor stroke. Interv Neuroradiol 2015 Aug;21(4):511-9.

\*Kozak O, et al. High risk of recurrent ischemic events among patients with deferred intracranial angioplasty and stent placement for symptomatic intracranial atherosclerosis. Neurosurgery 2011 Aug;69(2):334-42.

\*Kurre W, et al. In-hospital complication rates after stent treatment of 388 symptomatic intracranial stenoses: results from the INTRASTENT multicentric registry. Stroke 2010 Mar;41(3):494-8.

\*Kurre W, et al. Complication rates using balloon-expandable and self-expanding stents for the treatment of intracranial atherosclerotic stenoses: Analysis of the INTRASTENT multicentric registry. Neuroradiol 2012 Jan;54(1):43-50.

Kwon HM, et al. Frequency, risk factors, and outcome of coexistent small vessel disease and intracranial stenosis: results from the stenting and aggressive medical management for preventing recurrent stroke in intracranial stenosis (SAMMPRIS) Trial. JAMA Neurol 2016 Jan 1;73(1):36-42.

\*Lanfranconi S, et al. Stenting for the treatment of high-grade intracranial stenoses. J Neurol 2010 Nov;257(11):1899-1908.

Lee KY, et al. Undersized angioplasty and stenting of symptomatic intracranial tight stenosis with Enterprise: evaluation of clinical and vascular outcome. Interv Neuroradiol 2016 Apr;22(2):187-95.

\*Levy EI, et al. Midterm clinical and angiographic follow-up for the first Food and Drug Administration-approved prospective, single arm trial of primary stenting for stroke: SARIS (Stent-Assisted Recanalization for Acute Ischemic Stroke). Neurosurgery 2011 Oct;69(4):915-20.

\*Li J, et al. Wingspan stent for high-grade symptomatic vertebrobasilar artery atherosclerotic stenosis. Cardiovasc Intervent Radiol 2012 Apr;35(2):268-78.

Li TX, et al. Wingspan stenting for severe symptomatic intracranial atherosclerotic stenosis in 433 patients treated at a single medical center. PLoS One 2015 Sep 30;10(9):e0139377.

Li ZH, et al. Current status and future perspective of stenting for symptomatic intracranial atherosclerotic disease: a meta-analysis. Biomed Res Int 2017;2017:3258681.

Liu J, et al. Correlation studies and literature review of medullary artery occlusion after intracranial vertebral artery stenting. World Neurosurg 2019 Feb;122:665-670.

Liu L, et al. Stenting for symptomatic intracranial vertebrobasilar artery stenosis: 30-day results in a high-volume stroke center. Clin Neurol Neurosurg 2016 April;143:132-138.

Lutsep HL, et al. Outcome in patients previously on antithrombotic therapy in the SAMMPRIS trial: subgroup analysis. Stroke 2015 Mar;46(3):775-9.

Lutsep HL, et al. Does stenting versus aggressive medical therapy trial support stenting for subgroups with intracranial stenosis? Stroke 2015 Nov;46(11):3282-4.

Maio Z, et al. Outcomes of tailored angioplasty and/or stenting for symptomatic intracranial atherosclerosis: a prospective cohort study after SAMMPRIS. J Neurointerv Surg 2015 May;7(5):331-5.

## **Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING**

**Policy Number: 7.01.70**

**Page: 9 of 11**

Maio Z, et al. Thirty-day outcome of a multicenter registry study of stenting for symptomatic intracranial artery stenosis in China. Stroke 2015 Oct;46(10):2822-9.

\*Marks MP, et al. Angioplasty for symptomatic intracranial stenosis: clinical outcome. Stroke 2006 Apr;37(4):1016-20.

Markus HS, et al. Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT. Health Technol Assess 2019 Aug;23(41):1-30.

\*Mazighi M, et al. Prospective study of symptomatic atherothrombotic intracranial stenoses: the GESICA study. Neurol 2006 Apr 25;66(8):1187-91.

\*Meyers PM, et al. Indications for the performance of intracranial endovascular neurointerventional procedures: a scientific statement from the American Heart Association Council on Cardiovascular Radiology and Intervention, Stroke Council, Council on Cardiovascular Surgery and Anesthesia, Interdisciplinary Council on Peripheral Vascular Disease, and Interdisciplinary Council on Quality of Care and Outcomes Research. Circulation 2009 Apr;119(16):2235-49.

\*Miao ZR, et al. Treatment of symptomatic middle cerebral artery stenosis with balloon-mounted stents: long-term follow-up at a single center. Neurosurgery 2009 Jan;64(1):79-84.

Nakashima T, et al. Long-term effects on preventing stroke after endovascular treatment or bypass surgery for intracranial arterial stenosis. J Stroke Cerebrovasc Dis 2019 Apr;28(4):1107-1112.

\*National Institute for Health and Clinical Excellence (NICE). Endovascular stent insertion for intracranial atherosclerotic disease. Interventional Procedure Guidance 429. 2012 Jul [<https://www.nice.org.uk/guidance/ipg429>] accessed 1/8/20.

Nordmeyer H, et al. Angioplasty and stenting of intracranial arterial stenosis in perforator-bearing segments: a comparison between the anterior and the posterior circulation. Front Neurol 2018 Jul 9;9:533.

Padalia A, et al. Percutaneous transluminal angioplasty with stent placement versus best medical therapy alone in symptomatic intracranial arterial stenosis: a best evidence review. Cureus 2018 Jul 16;10(7):e2988.

Park SC, et al. Long-term outcome of angioplasty using a Wingspan stent, post-stent balloon dilation and aggressive restenosis management for intracranial arterial stenosis. Clin Neuroradiol 2019 May 23. [Epub ahead of print]

Peng G, et al. Submaximal primary angioplasty for symptomatic intracranial atherosclerosis: peri-procedural complications and long-term outcomes. Neuroradiology 2019 Jan;61(1):97-102.

\*Powers WJ, et al. Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial. JAMA 2011 Nov 9;306(18):1983-92.

\*Qureshi AI, et al. Clinical and angiographic results of dilatation procedures for symptomatic intracranial atherosclerotic disease. J Neuroimag 2005 Jul;15(3):240-9.

\*Sacco RL, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention. Stroke 2006;37:577– 617.

\*Schumacher HC, et al. Reporting standards for angioplasty and stent-assisted angioplasty for intracranial atherosclerosis. Stroke 2009 May;40(5):e348-65.

Seyedsaadat SM, et al. Submaximal angioplasty in the treatment of patients with symptomatic ICAD: a systematic review and meta-analysis. J Neurointerv Surg 2019 Nov 20. [Epub ahead of print]

\*Siddiq F, et al. Rate of post-procedural stroke and death in SAMMPRIS trial eligible patients treated with intracranial angioplasty and/or stent placement in practice. Neurosurgery 2012 Jul;71(1):68-73.

\*SSYLVIA Study Investigators. Stenting of Symptomatic Atherosclerotic Lesions in the Vertebral or Intracranial Arteries (SSYLVIA): study results. Stroke 2004 Jun;35(6):1388-92.

## **Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING**

**Policy Number: 7.01.70**

**Page: 10 of 11**

\*Straube T, et al. Primary stenting of intracranial atherosclerotic stenoses. Cardiovasc Intervent Radiol 2005 May-Jun;28(3):289-95.

Sun X, et al. Risk factors of subacute thrombosis after intracranial stenting for symptomatic intracranial arterial stenosis. Stroke 2017 Mar;48(3):784-786.

\*Suri MF, et al. Intracranial angioplasty and/or stent placement in octogenarians is associated with a threefold greater risk of periprocedural stroke or death. J Endovasc Ther 2010 Jun;17(3):314-9.

\*Tang CW, et al. Stenting versus medical treatment for severe symptomatic intracranial stenosis. AJNR Am J Neuroradiol 2011 May;32(5):911-6.

\*Terada T, et al. Hemorrhagic complications after endovascular therapy for atherosclerotic intracranial arterial stenoses. Neurosurgery 2006 Aug;59(2):310-8; discussion 310-8.

Tsivgoulis G, et al. Percutaneous transluminal angioplasty and stenting for symptomatic intracranial arterial stenosis: a systematic review and meta-analysis. Ther Adv Neurol Disord 2016 Sept;9(5):351-358.

\*Turan TN, et al. Treatment of atherosclerotic intracranial arterial stenosis. Stroke 2009 Jun;40(6):2257-61.

Turan TN, et al. Is there a benefit from stenting on cognitive function in intracranial atherosclerosis? Cerebrovasc Dis 2016 Nov 5;43(1-2):31-35.

Turan TN, et al. Is there a benefit from stenting on cognitive function in intracranial atherosclerosis. Cerebrovasc Dis 2017;43(1-2):31-35.

von Schoenfeldt P, et al. Elective treatment of intracranial stenosis with the balloon-expandable Pharos Vitesse stent: 30-day stroke rate and complications. J Neurointerv Surg 2015 Mar;7(3):188-93.

Wang ZL, et al. Symptomatic intracranial vertebral artery atherosclerotic stenosis (> 70%) with concurrent contralateral vertebral atherosclerotic diseases in 88 patients treated with intracranial stenting. Eur J Radiol 2015 Sep;84(9):1801-4.

Wang ZL, et al. Severe symptomatic intracranial internal carotid artery stenosis treated with intracranial stenting: a single center study with 58 patients. Diagn Interv Radiol 2016 Mar-Apr;22(2):178-83.

\*Weber W, et al. Efficacy of stent angioplasty for symptomatic stenoses of the proximal vertebral artery. Eur J Radiol 2005 Nov;56(2):240-7.

\*Weber W, et al. Stent-angioplasty of intracranial vertebral and basilar artery stenoses in symptomatic patients. Eur J Radiol 2005 Aug;55(2):231-6.

Yaghi S, et al. Peri-procedural stroke or death in stenting of symptomatic severe intracranial stenosis. J Neurointerv Surg 2019 Sep 4. [Epub ahead of print]

Yin R, et al. Safety and efficacy analyses of angioplasty and stenting for severe intracranial arterial stenosis: a single-center retrospective study in China. Med Sci Monit 2015 Oct 31;21:3311-9.

\*Yoon W, et al. Symptomatic middle cerebral artery stenosis treated with intracranial angioplasty: experience in 32 patients. Radiol 2005 Nov;237(2):620-6.

Yu SCH, et al. Long-term evolutionary change in the lumen of intracranial atherosclerotic stenosis following angioplasty and stenting. Oper Neurosurg (Hagerstown) 2018 Feb 1;14(2):128-138.

\*Yu J, et al. Treatment of symptomatic intracranial atherosclerotic stenosis with a normal-sized Gateway™ balloon and Wingspan™ stent. J Int Med Res 2010 38(6):1968-74.

\*Zaidat OO, et al. Effect of a balloon-expandable intracranial stent vs medical therapy on risk of stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial. JAMA 2015 Mar 24-31;313(12):1240-8.

## **Medical Policy: ANGIOPLASTY OF INTRACRANIAL ATHEROSCLEROTIC STENOSES WITH OR WITHOUT STENTING**

**Policy Number: 7.01.70**

**Page: 11 of 11**

Zhang Q, et al. Comparison of stent versus medical therapy for symptomatic patients with intracranial atherosclerotic stenosis: a meta-analysis. J Neurol Sci 2017 Jan 15;372:272-278.

Zhao J, et al. Concomitant asymptomatic intracranial atherosclerotic stenosis increase the 30-day risk of stroke in patients undergoing symptomatic intracranial atherosclerotic stenosis stenting. J Stroke Cerebrovasc Dis 2018 Feb;27(2):479-485.

Zheng M, et al. Endovascular recanalization of non-acute symptomatic middle cerebral artery total occlusion and its short-term outcomes. Front Neurol 2019 May 15;10:484.

\*Zhou Y, et al. Angioplasty with stenting for intracranial atherosclerosis: a systematic review. J Int Med Res 2012;40(1):18-27.

Zhou Y, et al. Angioplasty and stenting for severe symptomatic atherosclerotic stenosis of intracranial vertebrobasilar artery. J Clin Neurosci 2019 May;63:17-21.

\*Key Article

### **KEY WORDS**

Angioplasty, Intracranial Circulation, Percutaneous Transluminal Angioplasty, Vertebrobasilar Stenosis, NeuroLink® System, Wingspan™ Stent.

### **CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS**

There is currently a National Coverage Determination (NCD) for percutaneous transluminal angioplasty (PTA) and a CMS decision memo related to percutaneous transluminal angioplasty (PTA) with intracranial stent placement. Please refer to the following NCD website for Medicare Members:

<http://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=201&ncdver=10&CoverageSelection=Both&ArticleType=All&PolicyType=Final&s=New+York+-+Upstate&CptHcpcsCode=36514&bc=gAAAABAAAAAAAA%3d%3d&>

#### **Decision memo:**

[http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=214&NcaName=Intracranial+Stenting+and+Angioplasty&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7CCAL%7CNCD%7CMEDCAC%7CTA%7CMCD&ArticleType=SAD%7CED&PolicyType=Final&s=---%7C5%7C6%7C66%7C67%7C44&KeyWord=percutaneous+transluminal+angioplasty+\(PTA\)+with+intracranial+stent+placement&KeyWordLookUp=Doc&KeyWordSearchType=Exact&kq=true&bc=IAAAABAACAAAAA%3D%3D&](http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=214&NcaName=Intracranial+Stenting+and+Angioplasty&SearchType=Advanced&CoverageSelection=Both&NCSelection=NCA%7CCAL%7CNCD%7CMEDCAC%7CTA%7CMCD&ArticleType=SAD%7CED&PolicyType=Final&s=---%7C5%7C6%7C66%7C67%7C44&KeyWord=percutaneous+transluminal+angioplasty+(PTA)+with+intracranial+stent+placement&KeyWordLookUp=Doc&KeyWordSearchType=Exact&kq=true&bc=IAAAABAACAAAAA%3D%3D&)